DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK MarketsDUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets

1 Day Clinical Trial Agreements Training Course: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets (Mar 18, 2026) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Clinical Trial Agreements: Key Legal, Regulatory and IP (Intellectual Property) Considerations for the EU (European Union) and UK Markets Training Course (Mar 18, 2026)” training has been added to ResearchAndMarkets.com’s offering.

The life sciences sector is heavily regulated and CTAs are some of the most important agreements for companies operating in this sector. Having appropriate CTAs in place is therefore essential for managing relationships between the different stakeholders, and apportioning risk and responsibilities between them. If appropriate contractual arrangements are not in place, a clinical trial may not receive approval or issues may arise with the integrity or validity of the data collected. Further, disputes between the parties can arise if responsibilities are not clearly defined in the agreement.

This intensive short course provides essential insights into the legal framework governing clinical trials in the EU and UK, ensuring compliance, protecting intellectual property and managing liability risks.

The expert speakers will explain the dynamic and increasingly demanding regulatory and data protection landscape to better inform those negotiations and drafting these agreements.

Benefits of attending

By attending this seminar you will:

  • Learn about the regulatory framework concerning clinical trials in the EU and the UK
  • Understand the EU Clinical Trial Regulation and UK Human Use (Clinical Trials) (Amendment) Regulations 2024
  • Examine the roles and obligations of stakeholders including sponsors, CROs, investigators, and ethics committees
  • Navigate clinical trials approval, ethical approvals, policy issues, and the legal risks of non-compliance
  • Master informed consent, clinical trial transparency, and compensation models to mitigate legal exposure
  • Learn how to protect IP rights in clinical trials, draft strong confidentiality agreements, and manage publication clauses.

Who Should Attend:

This course has been specially designed for:

  • Lawyers and in-house legal teams
  • Contract managers
  • Clinical contract specialists
  • Clinical trial managers and professionals
  • R&D staff
  • Regulatory specialists
  • And CROs, sponsors and healthcare organisations looking to stay ahead in an evolving legal landscape.

Key Topics Covered:

Overview of the regulation of clinical trials – the legal framework governing clinical trials in the EU and the UK

  • What a clinical trial is and the types of clinical trials
  • Who the stakeholders are and their roles and obligations
  • EU regulatory framework under the Clinical Trial Regulation 536/2014/EU and the Clinical Trials Information System (CTIS)
  • UK framework post Brexit under the Human Use (Clinical Trials) (Amendment) Regulations 2024
  • Clinical trial approval, ethics approval and policy issues (eg Health Research Authority approval)
  • What could happen if a clinical trial is not conducted in accordance with the law

Consent, data and IP rights

Sponsors and CROs must meet obligations relating to transparency, participant consent and data protection in clinical trials. In turn, those obligations have an impact on parties’ liability risks and IP rights. This session will examine:

  • Participant consent and liability risks:
    • Transparency obligations and the publication of clinical trials outcomes
    • How transparency and consent interact with liability risks, including:
      • Compensation models
      • Clinical trials insurance
      • Product liability risks for licensed products
  • Data protection:
    • Overview of the requirements
    • Use of patient data during and after a clinical trial (particularly in light of the 3/2019 guidance from the European Data Protection Board)
  • Intellectual property rights:
    • Relevant IP rights associated with clinical trials
    • How to best protect any accruing IP rights
    • Drafting and negotiating of IP rights, confidentiality and publication clauses

Final questions

For more information about this training visit https://www.researchandmarkets.com/r/6n17d8

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
1 Logo
1 Price(1)
$0.008486
$0.008486$0.008486
+7.88%
USD
1 (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Fed Decides On Interest Rates Today—Here’s What To Watch For

Fed Decides On Interest Rates Today—Here’s What To Watch For

The post Fed Decides On Interest Rates Today—Here’s What To Watch For appeared on BitcoinEthereumNews.com. Topline The Federal Reserve on Wednesday will conclude a two-day policymaking meeting and release a decision on whether to lower interest rates—following months of pressure and criticism from President Donald Trump—and potentially signal whether additional cuts are on the way. President Donald Trump has urged the central bank to “CUT INTEREST RATES, NOW, AND BIGGER” than they might plan to. Getty Images Key Facts The central bank is poised to cut interest rates by at least a quarter-point, down from the 4.25% to 4.5% range where they have been held since December to between 4% and 4.25%, as Wall Street has placed 100% odds of a rate cut, according to CME’s FedWatch, with higher odds (94%) on a quarter-point cut than a half-point (6%) reduction. Fed governors Christopher Waller and Michelle Bowman, both Trump appointees, voted in July for a quarter-point reduction to rates, and they may dissent again in favor of a large cut alongside Stephen Miran, Trump’s Council of Economic Advisers’ chair, who was sworn in at the meeting’s start on Tuesday. It’s unclear whether other policymakers, including Kansas City Fed President Jeffrey Schmid and St. Louis Fed President Alberto Musalem, will favor larger cuts or opt for no reduction. Fed Chair Jerome Powell said in his Jackson Hole, Wyoming, address last month the central bank would likely consider a looser monetary policy, noting the “shifting balance of risks” on the U.S. economy “may warrant adjusting our policy stance.” David Mericle, an economist for Goldman Sachs, wrote in a note the “key question” for the Fed’s meeting is whether policymakers signal “this is likely the first in a series of consecutive cuts” as the central bank is anticipated to “acknowledge the softening in the labor market,” though they may not “nod to an October cut.” Mericle said he…
Share
BitcoinEthereumNews2025/09/18 00:23
Markets await Fed’s first 2025 cut, experts bet “this bull market is not even close to over”

Markets await Fed’s first 2025 cut, experts bet “this bull market is not even close to over”

Will the Fed’s first rate cut of 2025 fuel another leg higher for Bitcoin and equities, or does September’s history point to caution? First rate cut of 2025 set against a fragile backdrop The Federal Reserve is widely expected to…
Share
Crypto.news2025/09/18 00:27
Solana zakt onder 130 dollar terwijl whales verschuiven

Solana zakt onder 130 dollar terwijl whales verschuiven

De koers van Solana is onder de grens van 130 dollar gezakt. Tegelijkertijd verschuift de aandacht van een deel van de grote investeerders. Nieuwe meme coins in
Share
Coinstats2025/12/27 23:46